DMAC Key Statistics, Chart & Performance
The current stock price of DMAC is 8.16 USD. In the past month the price decreased by -12.73%. In the past year, price increased by 54.84%.
DMAC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About DMAC
Company Profile
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 27 full-time employees. The company went IPO on 2008-01-04. The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
Company Info
DIAMEDICA THERAPEUTICS INC
301 Carlson Parkway, Suite 210
Minneapolis MINNESOTA 55447 US
CEO: Rick Pauls
Employees: 27
Phone: 17634965454
DIAMEDICA THERAPEUTICS INC / DMAC FAQ
What does DIAMEDICA THERAPEUTICS INC do?
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 27 full-time employees. The company went IPO on 2008-01-04. The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
What is the stock price of DIAMEDICA THERAPEUTICS INC today?
The current stock price of DMAC is 8.16 USD. The price decreased by -2.28% in the last trading session.
Does DMAC stock pay dividends?
DMAC does not pay a dividend.
How is the ChartMill rating for DIAMEDICA THERAPEUTICS INC?
DMAC has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists DMAC stock?
DMAC stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of DMAC stock?
DIAMEDICA THERAPEUTICS INC (DMAC) operates in the Health Care sector and the Biotechnology industry.
Can you provide the number of employees for DIAMEDICA THERAPEUTICS INC?
DIAMEDICA THERAPEUTICS INC (DMAC) currently has 27 employees.
DMAC Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to DMAC. When comparing the yearly performance of all stocks, DMAC is one of the better performing stocks in the market, outperforming 89.84% of all stocks.
DMAC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DMAC. While DMAC seems to be doing ok healthwise, there are quite some concerns on its profitability.
DMAC Financial Highlights
Over the last trailing twelve months DMAC reported a non-GAAP Earnings per Share(EPS) of -0.71. The EPS decreased by -26.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.96% | ||
| ROE | -61.85% | ||
| Debt/Equity | 0 |
DMAC Forecast & Estimates
11 analysts have analysed DMAC and the average price target is 15.81 USD. This implies a price increase of 93.75% is expected in the next year compared to the current price of 8.16.